Opioid Free Anesthesia in Bariatric Surgery

Postoperative Pain Clinical Trial

Official title:

Opioid Free Anesthesia in Bariatric Surgery: A Prospective, Double-blinded, Randomized, Controlled Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03507634
• Other study ID #: LAUMCRH.HB2.28/Mar/2018
• Status: Completed
• Phase: N/A
• Start date: April 11, 2018
• Est. completion date: June 30, 2020

Study information

• Verified date: September 2020
• Source: Lebanese American University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study compares the intraoperative opioid free anesthesia approach in laparoscopic bariatric surgery to a conventional opioid- based anesthesia. Half of participants will receive opioid free anesthesia with dexmedetomidine, lidocaine and ketamine while the other half will receive opioid based anesthesia with fentanyl, remi-fentanyl and ketamine

Description:

Since optimal analgesia for the obese patients undergoing bariatric surgeries has always been challenging, and knowing the comorbidities and physiological changes in this population, use of opioid-sparing agents during anesthesia has attracted substantial research.the use of opioids in the perioperative period in obese patients is associated with an increased risk of complications . They are especially more sensitive to the respiratory depressant effect of opioids , thus any analgesic alternative without further compromising airway tone would be a desirable choice.

Dexmedetomidine is a selective alpha-two adrenergic receptor agonist that has antinociceptive, analgesic and sedative properties, without compromising airway tone and reflexes .

Lidocaine, a local anesthetic that has been shown to be an effective multimodal strategy to minimize postoperative pain was evaluated in one study involving obese patients undergoing bariatric surgery. Its usage was associated with an improved quality of recovery compared to placebo .

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: June 30, 2020
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age group: 18-65 years old

• American Society of Anesthesiologists (ASA )class I and II

• Indicated laparoscopic bariatric surgery

Exclusion Criteria:

• Renal, hepatic or cardiac insufficiency

• Positive pregnancy test

• Alcohol or drug abuse

• Psychiatric disease

• History of chronic pain

• Allergy or contraindication to any of the study drugs

Related Conditions & MeSH terms

• Bariatric Surgery Candidate
• Opioid Use
• Postoperative Nausea and Vomiting
• Postoperative Pain
• Vomiting

Intervention

Drug:
• Opioid free Anesthesia dexmedetomidine and lidocaine
Opioid free anesthesia with dexmedetomidine and lidocaine
• Opioid based anesthesia Fentanyl and Remifentanyl
Opioid based anesthesia with Fentanyl and Remifentanyl

Locations

Country	Name	City	State
Lebanon	LAU Medical Center	Beirut

Sponsors (1)

Lead Sponsor	Collaborator
Lebanese American University

Country where clinical trial is conducted

Lebanon, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postoperative pain score for 48 hours	Measure the pain score using the Visual Analogue Scale (VAS), The Visual Analogue Scale (VAS) consists of a straight line with the endpoints defining extreme limits such as 'no pain at all' and 'pain as bad as it could be' The patient is asked to mark his pain level on the line between the two endpoints. The distance between 'no pain at all' and the mark then defines the subject's pain. The score ranges from 0 to 100 mm. A higher score indicates greater pain intensity. The distribution pain is the following:no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).Postoperative pain will be measured using Verbal Analogue Scale (VAS) at 0, 1, 2, 4, 6, 12, 18, and 24 and every 6 hours up to 48 hours post surgery.	48 hours postoperative
Secondary	Postoperative morphine consumption at the PACU (Post Anesthesia Care Unit)	After the surgery the patient will go to the PACU (Post Anesthesia Care Unit). the patient will receive morphine if the pain score is more than 4. the total dose of morphine in mg (milligrams) will be documented.	2 hours postoperative
Secondary	Postoperative morphine consumption at the surgical ward for 48 hours	Post-operative opioid consumption will be based on the amount in mg (milligrams) of opioid required in the 48 hours postoperative.	48 hours postoperative
Secondary	Postoperative morphine Side effects: Sedation score .for 48 hours	Sedation score: 0 alert; Mild, drowsy , easy to awake; moderate, easy to arouse; Severe: somnolent difficult to arouse 4:sleeping The Sedation score will be documented at 0, 1, 2, 4, 6, 12, 18, and 24 hours and then every 6 hours up to 48 hours.	48 hours postoperative
Secondary	Postoperative morphine Side effects:Respiratory depression for 48 hours	Assess the respiratory rate : The number of breaths per minute. In practice, the respiratory rate is usually determined by counting the number of times the chest rises or falls per minute.; The respiratory rate will be documented at 0, 1, 2, 4, 6, 12, 18, and 24 hours and then every 6 hours up to 48 hours.	48 hours postoperative
Secondary	Postoperative morphine Side effects: Nausea vomiting for 48 hours	Degree of nausea vomiting using the verbal rating score from 0 to 10 : 0= no nausea/ Vomiting, 10: worst possible nausea vomiting.; The degree of nausea vomiting will be documented at 0, 1, 2, 4, 6, 12, 18, and 24 hours and every 6 hours thereafter up to 48 hours.	48 hours postoperative
Secondary	Postoperative morphine Side effects: Itching for 48 hours	Itching: presence or absence The presence or absence of itching will be documented at 0, 1, 2, 4, 6, 12, 18, and 24 hours and every 6 hours thereafter up to 48 hours.	48 hours postoperative